Psoriasis | Patient Profiler | US | 2018
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe patient population, who cannot be adequately controlled with topical agents. The dominance of the TNF-alpha inhibitors and IL-12/23 Stelara (Janssen) are being challenged by the introduction of the highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of Novartis’s Cosentyx has been remarkable in the first two years postlaunch, but it faces competition from the new IL-17 inhibitors, in particular Eli Lilly’s Taltz, and the first-in-class IL-23 inhibitor, Janssen’s Tremfya. In addition, Celgene’s oral PDE-4 inhibitor, Otezla, has been approved for over four years in the United States and is gaining steady uptake in early lines of therapy. Analysis of claims data and electronic health records provides an objective lens to see how physicians prescribe therapies and the clinical profiles of treated patients.
Questions Answered
- What is the patient share in psoriasis for IL-17 and IL-23 inhibitors and other key segments?
- What are the demographic characteristics and clinical profiles of psoriasis patients on biologics and Otezla?
- What are the key risk factors, comorbidities, and coprescribed/additional therapies by patient segment for psoriasis?
- How do psoriasis patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?
- What are the reimbursed and out-of-pocket costs?
- What insurance type do psoriasis patients have?
Product Description
Patient Profiler provides disease-specific, patient-level analysis of key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.
